Abstract
Ensifentrine is a novel inhalational phosphodiesterase (PDE)3 and PDE4 inhibitor which improves bronchodilation and decreases inflammatory markers by acting locally on the bronchial tissue, with minimal systemic effects. Both preclinical and clinical trials have demonstrated benefits of this therapy, including improvement in lung function and reduction in exacerbations. This therapy is currently under review by the US Food and Drug Administration with a decision expected in 2024.
Disclosure
Drs. Faruqi and Khan report no conflicts of interest. Dr. Mannino is a consultant to GlaxoSmithKline, AstraZeneca, Regeneron, Genentech and The COPD Foundation, receives royalties from Up to Date, and is an expert witness on behalf of people suing the tobacco and vaping industries.